AGIO
32.18 USD
+3.25%
Today
+6.11%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 10:59 PM
Tue
4:30 PM ~ 10:59 PM
Wed
4:30 PM ~ 10:59 PM
Thu
4:30 PM ~ 10:59 PM
Fri
4:30 PM ~ 10:59 PM
Sat
Closed
Information
Name
Agios Pharmaceuticals
Currency
USD
Market Cap
1.86B
Avg Daily Volume
1.09M
52 Week High
46 USD
52 Week Low
22.24 USD
Trading Hours
See hours
Business Summary
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Top News
Agios
+1.97%
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
tradingview.com
44m ago
Agios
+1.97%
Will FDA Review Delay Change Agios Stock Narrative
finance.yahoo.com
6h ago
Agios
+1.97%
Weekly Recap: FDA extends mitapivat review and analyst starts Buy coverage
tradingview.com
2d ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
